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Total Synthesis of Millingtonine 
Patrick D. Brown, and Andrew L. Lawrence* 
 
Abstract: Millingtonine is a glycosidic alkaloid that exists as a pair of 
pseudo-enantiomeric diastereomers. Consideration of the likely 
biosynthetic origins of this unusual natural product has resulted in 
the development of a seven-step total synthesis. Results from this 
synthetic work provide evidence in support of a proposed network of 
biosynthetic pathways that can account for the formation of several 
phenylethanoid natural products. 
In 1996 Yamasaki and co-workers isolated the alkaloid 
millingtonine (1) from Millingtonia hortensis, an ornamental 
Bignonia plant more commonly known as the Indian Cork Tree.[1] 
Millingtonine (1) was isolated as a mixture of two diastereomeric 
alkaloids, which contain a molecular framework not previously 
known to exist in the natural world. Conceptually, but not 
biosynthetically (vide infra), millingtonine (1) can be considered 
to consist of a racemic aglycone core that is ‘resolved’ into two 
pseudo-enantiomeric diastereomers by the attachment of a pair 
of β-D-glucopyranosyl units. Biosynthetically, millingtonine (1) is 
likely constructed from two shikimate-derived C6C2 units, linked 
together by an ornithine-derived C4N unit (Scheme 1). No 
biosynthetic pathway towards millingtonine (1) has been 
proposed and, as commented upon by the isolation team, “the 
mechanism of insertion of this (C4N) unit between the two C6C2 
units is unknown”.[1] 
There has been one previous total synthesis of millingtonine 
(1), reported in 2012 by the research groups of Ley, Kirschning 
and Baxendale.[2] The execution of a total synthesis of this 
alkaloid is an impressive achievement, with the intermediate 
structures en-route to millingtonine (1) reported to be 
“exceedingly prone” to rearrangement reactions. In total, the 
Ley-Kirschning-Baxendale synthesis required twelve linear steps 
from commercially available materials (sixteen steps in total) and 
produced milligram quantities of material. We were hopeful that 
if we could gain new insight into how nature synthesizes 
millingtonine (1) we might be able to develop a new, more step-
economical, synthetic strategy. 
Our previous biomimetic studies on other phenylethanoid 
natural products provided some important clues as to the 
potential origins of millingtonine (1).[3] We considered that a 
phenylethanoid glycoside 2, which contains an ornithine-derived 
N-linked putrescine unit, might represent a reasonable 
biosynthetic precursor. Our biosynthetic proposal, which is 
shown in Scheme 2, involves a network of pathways that can 
account for the formation of several structurally distinct natural 
products isolated from Bignoniaceae plants: cornoside (3),[4] 
rengyolone (4),[5] incarviditone (5),[6] incarvilleatone (6),[7] 
incargranine B (7),[8] and millingtonine (1).[1]  
 
Scheme 1. Structure and retro-biosynthetic analysis of millingtonine (1). Glc = 
D-glucopyranosyl. 
In our proposal, diamine 2 can undergo an oxidative 
dearomatization to form imine 8 (Scheme 2; Pathway 1), which 
following hydrolysis would give the known para-quinol natural 
product cornoside (3). It has been shown that cleavage of the 
glycosidic bond in cornoside (3) results in concomitant oxa-
Michael cyclisation to give the racemic natural product 
rengyolone (4).[9] We previously investigated a biomimetic 
domino-Michael dimerization of rengyolone (4) to access 
incarviditone (5),[3a] a racemic homochiral dimer. From our 
synthetic studies we were able to reassign the relative 
stereochemistry of incarviditone (5) and isolate an unexpected 
racemic heterochiral dimer, which was subsequently reported as 
a natural product named incarvilleatone (6).[7] An alternative 
biosynthetic pathway from diamine 2 (Scheme 2; Pathway 2) 
involves oxidative deamination to give amino-aldehyde 9, which 
would be expected to undergo intramolecular condensation to 
give enamine 10. We predicted enamine 10 would then undergo 
rapid dimerization with its corresponding iminium ion 11, which 
formed the basis of our previous structural reassignment and 
biomimetic synthesis of incargarnine B (7).[3b] [*] P. D. Brown, Dr. A. L. Lawrence 
EaStCHEM School of Chemistry 
University of Edinburgh 
Joseph Black Building, David Brewster Road, Edinburgh, EH9 3FJ 
(UK) 
E-mail: a.lawrence@ed.ac.uk 
 Supporting information for this article can be found under: 
  
COMMUNICATION          
 
 
 
 
 
Scheme 2. Proposed network of biosynthetic pathways towards a family of plant-derived phenylethanoid natural products, including millingtonine (1). Glc = D-
glucopyranosyl. 
With these two divergent biosynthetic pathways in mind we 
recognized the possibility that the two pathways could re-
converge to give millingtonine (1) (Scheme 2; Pathway 3). Thus, 
a Michael reaction between enamine 10 and cornoside (3) would 
give an intermediate iminium ion 12, which would rapidly ring-
close through an oxa-Mannich reaction to give millingtonine (1). 
Therefore, in our proposed biogenesis, the two diastereomers of 
millingtonine (1) are the result of a lack of stereochemical 
influence exerted by the sugars of enamine 10 and cornoside (3) 
in a crossed-dimerization, rather than a late-stage glucosidation 
of a racemic aglycone. 
In our previous work (Scheme 3),[3b] the incargranine B 
framework (13) was accessed through a biomimetic domino 
Mannich/SEAr (electrophilic aromatic substitution) reaction 
sequence, initiated by acidic-deprotection of acetal-protected 
amino-aldehyde 14.[10] It was envisaged that having para-quinol 
15[11] present under these acidic deprotection conditions would 
allow for a biomimetic crossed-dimerization to occur to give the 
millingtonine framework. However, after extensive 
experimentation, screening various acidic reaction conditions, no 
crossed-dimerizations could be achieved. Only formation of the 
incargranine B and dia-incargranine B aglycone structures (13 & 
16) was observed. It was concluded that the domino 
Mannich/SEAr reaction sequences, en-route to the incargranine 
B frameworks, are too fast for crossed-dimerization to compete. 
We considered, however, that a window of opportunity for 
crossed-dimerization might exist if an N-aryl enamine (akin to 
17) could be accessed whilst avoiding formation of the highly 
electrophilic N-aryl iminium species (akin to 18). 
 
Scheme 3. Previously reported biomimetic synthesis of the incargranine B 
aglycone 13.[3b] TBS = tert-butyldimethylsilyl. 
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Scheme 4. Biomimetic total synthesis of millingtonine (1). Boc = tert-butyloxycarbonyl, TMSOTf = trimethylsilyl trifluoromethanesulfonate, Glc = D-glucopyranosyl, 
Piv = pivaloyl, TFA = trifluoroacetic acid. 
Many strategies were investigated before we settled upon an 
alkene isomerization approach, using transition-metal hydride 
catalysis.[12] Thus, commercially available 4-aminophenethyl 
alcohol 19 was protected as an acid-labile tert-butoxycarbamate 
before a β-selective glucosidation was achieved, using the 
pivaloyl-protected trichloroacetimidate 20 (Scheme 4).[13] Under 
the acidic glucosidation reaction conditions deprotection of 
aniline 21 occurred in situ to give the pivaloyl-protected 
glucoside 22 in 53-55% yield over the two steps. Condensation 
of aniline 22 with (Z)-1,4-dichlorobut-2-ene then gave N-aryl-2,5-
dihydropyrrole 23 in 50-52% yield.[14] It was found that the 
commercially available RhHCO(PPh3)4 was a competent catalyst 
for the isomerization of skipped enamine 23 into the conjugated 
enamine 24.[15] All efforts to purify and isolate enamine 24, 
however, were met with failure. Therefore, the search for 
suitable reaction conditions for cross-dimerization of enamine 24 
with para-quinol 25, which was prepared in 4 steps from 
tyrosol,[16] were pursued using freshly prepared solutions of 
enamine 24. Pyrrolidine was investigated, in the hope of 
establishing an iminium-organocatalytic cycle,[17] and gratifyingly 
led to crossed-dimerization for the first time, albeit in very low 
yield. Control experiments, however, revealed that the beneficial 
effect of adding pyrrolidine was down to the unexpected 
formation of an aminal intermediate 26.[15] Furthermore, inclusion 
of pyrrolidine at the beginning of the rhodium-hydride-catalyzed 
isomerization reaction was found to result in quantitative 
conversion of alkene 23 to aminal 26.[18] Pivaloyl-protected 
cornoside 25 was then added to this freshly prepared solution 
resulting in the formation of a 1:1 diastereomeric mixture of 
crossed-dimers 27 in 50% isolated yield. Formation of the 
cis,syn,cis-isomers 27 was an unexpected and presumably 
kinetically controlled outcome, as we anticipated the desired 
cis,anti,cis ring system would be thermodynamically more 
favorable. Our kinetic versus thermodynamic reasoning was 
shown to be sound, as exposure of the cis,syn,cis-isomers 27 to 
acidic conditions resulted in isomerization to the desired 
cis,anti,cis-isomers 28 in 56-73% yield (Scheme 4). Presumably 
this isomerization occurs via an acid-catalyzed retro-oxa-
Mannich/iminium-epimerization/oxa-Mannich reaction sequence. 
Finally, removal of the pivaloyl groups under basic conditions 
gave over 50 mg of millingtonine (1) in 67% yield. Thus we had 
successfully synthesized millingtonine (1) in a longest linear 
sequence of seven steps from commercially available materials 
(ten steps in total), which compares favorably to the previous 
state-of-the-art.[2] 
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Scheme 5. a, Mechanistic speculation for our successful crossed-dimerization. b, Plausible biosynthetic pathway towards dia-millingtonine (33) involving vitamin 
B6 (i.e., pyridoxal phosphate) as a co-enzyme. Glc = D-glucopyranosyl. 
The successful crossed-dimerization of aminal 26 with para-
quinol 25 (Scheme 4) stands in stark contrast to the exclusive 
homo-dimerization observed when using acetal 14 (Scheme 3). 
Our failure to cross-dimerize acetal 14 was attributed to the 
formation of a highly reactive N-aryl iminium species 18, which 
leads to very fast and essentially irreversible domino 
Mannich/SEAr reaction sequences (Scheme 3). In our successful 
crossed-dimerization, however, we still isolate an 14% yield of 
homo-dimers (29 and 30) (Scheme 4), indicating that an N-aryl 
iminium ion must still be formed under these reaction conditions. 
How then can crossed-dimerization compete? One possible 
explanation is that it is more favourable for the endocyclic C–N 
bond of aminal 26 to cleave, in preference to the exocyclic C–N 
bond, to give the acyclic iminium ion 31 (Scheme 5a). Therefore, 
the problematic N-aryl iminium species is present at lower 
concentration and can also be rapidly trapped by the pyrrolidine. 
Thus enamine 32, which would also be expected to be more 
nucleophilic than the N-aryl enamine 24, has a sufficient window 
of opportunity to react with para-quinol 25 (Scheme 5a). It is 
interesting to consider whether this might, therefore, be 
indicative of a similar mechanism operating within the plant. 
Might pyrrolidine be mimicking the coenzyme-role of vitamin B6 
(i.e., pyridoxal phosphate) in an interrupted oxidative-
deamination reaction of diamine 2 (Scheme 5b)?[19] 
In summary, through synthesis alone we have been able to 
probe the feasibility of our proposed biogenesis of millingtonine 
(1). We have been able to obtain evidence in support of a unified 
network of biosynthetic pathways that can account for the 
formation of a family of phenylethanoid natural products. 
Crucially, these new biosynthetic insights have enabled the 
development of a highly step-economical total synthesis of 
millingtonine (1). Central to the development of this successful 
synthesis was the use of transition-metal hydride catalysis to 
access an otherwise unstable biomimetic intermediate, an 
approach we envisage will prove applicable to other biomimetic 
studies. The future isolation of the cis,syn,cis-isomer of 
millingtonine, namely dia-millingtonine (33), from the natural 
environment would represent a new case of ‘natural product 
anticipation’ – an essentially unique benefit of following 
biomimetic strategies in synthesis.[20] 
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Hidden symmetry: Millingtonine is a glycosidic alkaloid that exists as a pair of 
pseudo-enantiomeric diastereomers. Consideration of the likely biosynthetic origins 
of this unusual natural product has resulted in the development of a seven-step 
total synthesis. Results from this synthetic work provide evidence in support of a 
proposed network of biosynthetic pathways that can account for the formation of 
several phenylethanoid natural products. 
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